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TSP-1, a murine T cell specific proteinase, is expressed in cytolytic T lymphocytes and secreted upon their 
interaction with antigen bearing target cells. In searching for possible extracellular substrates of the enzyme 
in the physiological environment of cytolytic effector cells, we have investigated the proteolytic activity of 
TSP-1 on retroviral proteins. It is shown that reverse transcriptase derived from the retrovirus Moloney 
murine leukemia virus is inactivated by TSP-1 via limited proteolysis. The data suggest he possibility that 
cytolytic T lymphocytes are able to interfere with retroviral replication by secreting a serine proteinase which 
degrades viral proteins. 
Serine proteinase; Reverse transcriptase; Virus replication; (Cytolytic T cell) 
1. INTRODUCTION 
Cytolytic T lymphocytes play an important role 
in the host defense of viral infections. The findings 
that specific CTLs are able to lyse virus-infected 
syngeneic ells in culture [l] and to confer protec- 
tion against lethal viral infections in syngeneic 
mice [2-41 led to the concept that CTLs control 
viral replication in vivo by direct cytolysis of in- 
fected cells. However, direct evidence on the im- 
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portance of CTL-mediated cytolysis in the control 
of viral infections is still lacking. In addition, 
studies demonstrating secretion of lymphokines 
[5], including IFNy [6,7], by CTLs suggested the 
possibility of direct or indirect anti-viral activity 
exerted via soluble factors. Recently we [8,9] and 
others [lo-121 have described a serine pro- 
teinase/serine esterase(s), respectively, isolated 
from cloned murine CTLLs. The T cell-specific 
serine proteinase, termed TSP-1 [8] or 
synonymously granzyme A [lo], or SE1 [12], was 
shown (i) to be a disulfide-linked dimer with a 
molecular mass of 60 kDa, (ii) to have a highly 
restricted specificity [8], (iii) to be inducible in both 
T cell subsets - Lyt-2+ and L3T4+ - [ 13,141, (iv) 
to be expressed in all CTLLs and in some THLs 
tested so far [9], (v) to be associated with 
cytoplasmic granules of CTLs [10,12,15], and (vi) 
to be released into the extracellular space during 
CTL-target cell interaction [ 11,14,16]. Previous 
functional studies using the purified enzyme and a 
TSP-1 specific inhibitor have indicated that TSP-1 
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is involved in the process of cytolysis [16], in the 
control of the humoral immune response [8] and in 
lymphocyte extravasation [17,181. In searching for 
possible target structures of the secreted TSP-1 we 
have investigated whether viral proteins may serve 
as substrates for the T cell-specific enzyme. We 
now communicate that the enzyme RT associated 
with the retrovirus MoMuLV is inactivated by 
TSP-1 via limited proteolysis. Together with the 
finding that TSP-1 is specifically released from ef- 
fector cells upon contact with target cells these 
results suggest hat beside their cytolytic potential 
CTL might be able to control replication of 
retroviruses in vivo by a serine proteinase which 
degrades relevant viral structures. 
2. MATERIALS AND METHODS 
2.1. Materials 
Chromogenic substrates were obtained from 
either Bachem AG (A-16056, A-13102, A-16071; 
Bubendorf, Switzerland), AB Kabi Peptide 
Research (S-2302, S-2444, S-2266, S-2288, S-225 1, 
S-2586; Munchen, FRG) or from Boehringer 
Mannheim (Chromozymes PL, TR4, TH; FRG). 
Tissue kallikrein (791164) was from Boehringer 
Mannheim, pancreatic trypsin from Merck Darm- 
stadt (FRG) and plasma kallikrein (K 3126) from 
Sigma (Munchen, FRG). 
The enzyme inhibitors PMSF (P-7626) and PFR- 
CK were from Sigma, and Bachem, respectively. 
All other chemicals of highest purity available 
were from Roth (Karlsruhe, FRG), Merck, Phar- 
macia (Freiburg, FRG) and Sigma. [3H]DFP and 
[cu-32P]dATP were from Amersham (Braun- 
schweig, FRG). 
2.2. Purification of TSP-1 
Purification of TSP-1 from a long term culture 
CTLL 1.3E6 [19] was achieved as follows: 2-3 x 
lo9 cells of CTLL 1.3E6 (‘aged killer’ AK of 
C57BL/6 origin with specificity for P815 target 
cells) were disintegrated in lysis-buffer (0.01 mM 
Tris-HCl, pH 7.5, 0.1% Triton X-100) at 5 x lo7 
cells-ml-’ for 1 h on ice. Particulate material was 
removed at 2500 x g for 15 min. The resulting 
supernatant was saturated with 60% ammonium 
sulfate (NH&Sod, stirred for 2 h on ice. After- 
wards the sample was centrifuged at 40000 x g for 
30 min and the pellet discarded. The supernatant 
was dialysed overnight against 0.1 M Tris-HCl, 
pH 8.5, and then loaded onto an arginine- 
Sepharose column (10 ml packed volume, Phar- 
macia) previously equilibrated with 0.1 M Tris- 
HCl, pH 8.5. The column was washed with the 
same buffer, followed by 0.5 M arginine in 0.1 M 
Tris-HCl, pH 8.5. Eluted fractions (1 ml) were 
monitored by assaying 10~1 aliquots for 
amidolytic activity on PFR-NA. Protein was deter- 
mined in each fraction by the method of Bradford 
[20]. 0.5 M arginine eluted enzyme activity as a 
single peak, whereas practically no amidolytic ac- 
tivity could be detected in the pass-through. Active 
fractions (representing 15% of the initial activity) 
were pooled, dialysed against 0.1 M Tris-HCI, pH 
7.5, and loaded onto an anion-exchange column 
(Mono Q HR 515, 17-0547-01 Pharmacia) 
previously equilibrated in 0.1 M Tris-HCl, pH 7.5, 
and connected to a FPLC unit. Protein was eluted 
with a linear gradient of 1 M KC1 in 0.1 M Tris- 
HCl, pH 7.5 (O-100%). Fractions (1 ml) were col- 
lected and aliquots of each fraction tested for 
amidolytic activity on PFR-NA and protein as 
described above (a). Fractions with highest enzyme 
activity (between 150 and 250 mM KCl) repre- 
senting 0.6-3% of the initial activity were pooled, 
dialysed against 0.1 M Tris-HCl, pH 7.5, and 
stored frozen. For analysis by gel electrophoresis, 
20~1 of the purified enzyme preparation were 
mixed with 20,ul of sample buffer containing 
20 mM dithiothreitol (DTT) and 5% SDS and were 
heated to 95°C for 5 min. Subsequently, 20 ,~l of 
the sample were run on a 12.5% Laemmli gel [21] 
and silver stained. Alternatively, 20 ,~l of the sam- 
ple were affinity labeled by incubation with 1~1 
(= 5 &i; spec. act. 62.8 mCi/mmol) of [3H]DFP 
(Amersham) for 2 h at 37”C, boiled in SDS buffer 
in the presence of DTT and run on an SDS gel as 
described before. After electrophoresis, the gels 
were treated with Enlightning (New England 
Nuclear), dried and subjected to fluorography with 
Kodak X-Omat AR films at - 70°C using Quanta 
III intensifying screens. 
2.3. Assay for amidolytic activity 
Enzyme preparations were tested for amidolytic 
activity as follows: aliquots of test samples (in 
100 ,ul) were mixed with 100~1 of the individual 
chromogenic substrate (3 x 10m4 M) in 100 mM 
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Tris-HCl, pH 8.5, in microtiter plates (Nunclon, 
96-well multidish; Nunc, Wiesbaden, FRG). The 
enzyme activity was tested after 1 h at 37°C at 
405 nm by spectrophotometric reading of the 
chromophore products in microtiter wells. The 
molar absorption coefficient is 10.4 l/m01 per cm 
for 4-nitroaniline at 405 nm. An absorbance of 
0.01 was defined as 1 unit of amidolytic activity. 
TSP-1 was used at 75 ng, the commercially 
available t-kallikrein at 20 ng, p-kallikrein at 5 ~1 
of stock solution and pancreatic trypsin at 10 ng 
per well on the indicated chromogenic substrates. 
The enzyme activity was 125 U/pg for TSP-1, 
800 U/l pg t-kallikrein, 96 U/10 ~1 p-kallikrein 
and 530 U/pg pancreatic trypsin on the model pep- 
tide H-D-Pro-Phe-Arg-NA. 
2.6. Analysis of proteolytic degradation products 
by SDS-PAGE 
100 U cloned MoMuLV RT (BRL) were in- 
cubated with/without proteases for 2 h in 20 mM 
Tris-HCI, pH 8.0, at 37°C. Control reactions con- 
taining the protease inhibitors PFR-CK (1 mM) or 
PMSF (3 mM) were preincubated with the pro- 
tease alone for 30 min at 37°C before adding the 
reverse transcriptase. Degradation products were 
separated by electrophoresis on a PhastSystem 
equipment (Pharmacia, Freiburg, FRG) on a 
10-l 5 % gradient SDS-polyacrylamide gel after 
denaturation of the samples at 95°C for 5 min in 
10 mM dithiothreitol (DTT), 2.5% SDS. Proteins 
were visualized by silver staining. 
2.4. Assay for proteolytic activity 3. RESULTS 
Hydrolysis of the protein substrate azocoll by 
three related enzymes was determined as follows: 
the incubation mixture contained 5 mg azocoll 
(19493, Calbiochem, Frankfurt, FRG) and 1 sg of 
either TSP-1 or t-kallikrein or 25 ng of pancreatic 
trypsin in a total volume of 1.1 ml of 0.1 M Tris- 
HCl, pH 8.5. After 1 h incubation at 37°C changes 
in absorbance at 520 nm were recorded in the clear 
filtrate, previously freed from the insoluble azocoll 
as described [22]. Blank values, obtained in the 
absence of enzyme were subtracted in each case. 
3.1. General remarks 
2.5. Reverse transcriptase activity assay 
100 U cloned MoMuLV RT ( = 4 pmol = 1.1 pg 
protein; product information BRL, Karlsruhe, 
FRG) were incubated with/without serine pro- 
teinases for 2 h in 20 mM Tris-HCl, pH 8.0, at 
37°C. Control reactions containing the protease 
inhibitor PMSF (3 mM) were preincubated with 
the protease alone for 30 min at 37°C before 
adding the reverse transcriptase. Finally, reverse 
transcriptase activity was tested in a reaction mix- 
ture (50 ~1) containing 50 mM Tris-HCl, pH 7.5, 
75 mM KCl, 3 mM MgCl2, 30 mM ,&mercapto- 
ethanol, 40 U RNAsin (Biotek), 0.5 mM each of 
dCTP, dGTP, dTTP (Pharmacia) and 1 &Zi 
[a-32P]dATP (Amersham, 800 Ci/mmol), 
10 pg/ml oligo(dT)r2_,8 (Pharmacia) and 100 ng 
rabbit globin mRNA (BRL) according to Maniatis 
et al. [23]. The 32P-labeled cDNA products were 
run on a 5% polyacrylamide gel containing 5 M 
urea and visualized by autoradiography. 
Previous studies have shown that TSP-1 is a 
serine proteinase with a remarkably restricted 
specificity for the chromogenic substrate PFR-NA 
[8,9]. The finding that model peptides, synthesized 
according to the AA sequences at the cleavage site 
in native proteins, may imitate the structure 
following the bond split by the enzyme in natural 
substrates ([24] and Wolf, H.D., personal com- 
munication) suggested that TSP-1 may recognize 
the same or a similar array of AA sequences on 
proteins as well. This is also substantiated by a 
study reporting the identification and isolation of 
a hormone processing proteinase from yeast by ap- 
plying short model peptides, representing those se- 
quences of the precursor protein, where cleavage is 
thought to occur in vivo [25]. 
Based on these observations we used the peptide 
sequence PFR, which is most readily recognized by 
TSP-1 among the chromogenic substrates tested so 
far, to search for proteins containing this tripep- 
tide. By screening the Dayhoff, Doolittle and 
EMBL protein sequence databanks it became ob- 
vious that many proteins encoded by DNA and 
RNA viruses including retroviral core and 
envelope proteins and polymerases (reverse 
transcriptases) from AKR MuLV, AKV MuLV, 
Rauscher spleen focus-forming virus and from 
human immunodeficiency virus (HIV) as well as 
the trans-activating transcriptional regulatory pro- 
tein of HTLV-I and the putative protease of 
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HTLV-II contain PFR or very similar AA se- 
quences with L-arginine in position Pi. 
Although we realize that this finding may be ac- 
cidental and merely due to the composition of the 
databanks we felt it sufficiently worthwhile - also 
in view of the important role of CTLs in the con- 
trol of virus replication in vivo - to investigate 
whether TSP-1 is able to degrade and/or inactivate 
retroviral proteins, in particular RT, an enzyme 
essential for retroviral replication [26]. 
3.2. Comparison of substrate specificity of TSP-I 
and related serine proteinases 
TSP-1 used in this study was a homogeneous 
preparation as revealed by a single band with a 
molecular mass of 60 kDa (under nonreducing 
conditions) and by a broad band with a molecular 
mass of 30-35 kDa (under reducing conditions) 
(fig.1, and [15]). In addition, both molecular 
species (nonreduced and reduced) coincide with 
molecules labeled with [3H]DFP, a specific affinity 
ligand for serine proteinases (fig. 1). 
For a meaningful interpretation of the func- 
tional data shown here it was of importance to in- 
clude in the experimens in addition to TSP-1 other 
serine proteinases, with either highly restricted or 
less restricted proteolytic activities such as tissue 
(t)- and plasma (p)-kallikrein or pancreatic trypsin, 
respectively. Table 1 shows a comparison of the 
amidolytic activities of the enzymes. TSP-1, and 
both t- and p-kallikrein are ‘highly specific for 
arginine amides and are restricted to few substrates 
whereas pancreatic trypsin has a much less 
restricted specificity. When tested on the protein 
substrate azocoll, an insoluble, collagen-dye con- 
jugate [22], TSP-1 and t-kallikrein only showed 
marginal proteolytic activity whereas the same 
substrate was much more rapidly (> lOO-fold) 
hydrolysed by pancreatic trypsin (table 2). These 
results again emphasize the highly restricted pro- 
teolytic activities of TSP-1 as well as those of t- 
and p-kallikrein [28,29]. 
3.3. Effect of TSP-I on the polymerase activity of 
RT 
For the following study we used a commercially 
available preparation of recombinant RT from 
MoMuLV which is often taken as a prototype for 
mammalian RNA tumor viruses. Preparations of 
purified TSP-1, of t- and p-kallikrein and of pan- 
Fig.1. SDS-PAGE analysis of purified TSP-1. The 
purified enzyme was incubated with t3H]DFP before 
treatment with SDS as described in section 2. (A) 
Fluorogram of [3H]DFP-labeled protein. (B) Proteins 
stained with silver nitrate. 
creatic trypsin were adjusted to protein concentra- 
tions expressing similar amidolytic activity on the 
model peptide substrate PFR-NA and were in- 
cubated with aliquots of RTM,,M,,Lv. Alternatively, 
the enzyme preparations were pretreated with pro- 
teinase inhibitors PMSF and PFR-CK and then in- 
cubated with RTM,,M”~v. PMSF is a class specific 
inhibitor for most serine proteinases, including 
TSP-1 [8], t- and p-kallikrein and pancreatic tryp- 
sin [30]. PFR-CK had been synthesized as a 
specific inhibitor for TSP-1 according to the AA 
target sequence recognized by this serine pro- 
teinase on model peptide substrates [ 15,161. 
Residual activity of RTM~M”LV was tested in a 
reverse transcriptase assay system containing rab- 
bit globin mRNA and radioactively labeled 
nucleotides. Newly synthesized 32P-labeled cDNA 
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Table 1 
Substrate specificity of purified proteinases on model peptide substrates 
Substrates tested TSP- 1 Percent relative actvity of 
Kallikrein Kallikrein Trypsin 
(tissue) (plasma) (pancreatic) 
H-D-Pro-Phe-Arg-NA 100 62 100 12 
Bz-Phe-Val-Arg-NA 26 0 0 42 
Tos-Gby-Pro-Arg-NA 4 0 41 100 
H-D-Be-Pro-Arg-NA 25 5 73 81 
pyro-Glu-Gly-Arg-NA 0 0 0 85 
Bz-Be-Glu-Gly-Arg-NA 0 0 0 100 
Cbz-Val-Gly-Arg-NA 4 0 3 50 
H-D-Val-Leu-Arg-NA 25 100 67 36 
Tos-Gly-Pro-Lys-NA 4 0 5 46 
H-D-Val-Leu-Lys-NA 0 0 8 12 
Meo-Sue-Arg-Pro-Tyr-NA 0 0 0 0 
Boc-Ala-Ala-NA 0 0 0 0 
Purified TSP-1, t-kallikrein, p-kallikrein and pancreatic trypsin were tested against 
the substrates indicated. Amidolytic activity was determined as described in 
section 2 
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was separated on polyacrylamide gels and visual- 
ized by autoradiography. The polymerase activity 
of untreated RTM~M”LV in the system is indicated 
by a labeled DNA band of about 600 bases as ex- 
pected for rabbit globin mRNA (fig.2, lanes 
1,7,12). Pretreatment of RTM~M”LV with increasing 
concentrations of TSP-1 resulted in a dose- 
dependent reduction of polymerase activity (fig.2, 
lanes 2-5). Preincubation of TSP-1 with PMSF 
abolished this effect (fig.2, lane 6). Furthermore, 
enzyme activity of RTM,,M”Lv was also con- 
siderably reduced after incubation with t-kallikrein 
(fig.3, lanes 10,ll) and was totally abolished after 
treatment with pancreatic trypsin (fig3, lanes 
Table 2 
Hydrolysis of the protein substrate azocoll by TSP-1, t- 
kallikrein and pancreatic trypsin 
Hydrolysis (A/h per mg enzyme) 
TSP-1 t-Kallikrein Trypsin 
Azocoll 24 24 7600 
Purified TSP-1, t-kallikrein and pancreatic trypsin were 
tested for proteolytic activity on azocoll as described in 
section 2 
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13,14) at enzyme concentrations comparable to 
that of TSP-1. In contrast, p-kallikrein reduced 
polymerase activity of RTM~M~LV only marginally 
(fig.3, lanes 8,9). Inactivation of RTM~M~LV by 
pancreatic trypsin was reversed to a great extent 
after pretreatment of the enzyme with PMSF 
(fig.2, lane 15). The differential capacity of t- 
kallikrein vs p-kallikrein to inactivate RThl0~“r.v is 
not unexpected; in spite of their similar amidolytic 
activities, as observed on model peptide substrates, 
the two enzymes recognize different cleavage sites 
on the protein substrate high-molecular-mass 
kininogen [28,29]. Furthermore, low-molecular- 
mass kininogen was shown to be only a substrate 
for t- but not for p-kallikrein [29]. Thus, the 
results demonstrate that TSP-1 is able to efficiently 
inactivate RTM,_,M”Lv. Moreover the finding that 
the polymerase is only partially inactivated by t- 
kallikrein and not at all by p-kallikrein stresses the 
highly restricted substrate specificity of individual 
proteinases on native proteins. 
3.4. Cleavage of RT by TSP-I 
In order to investigate whether the inactivation 
of RTM,,M”Lv by TSP-1 and similar serine pro- 
teinases is accompanied by controlled proteolytic 
degradation, aliquots of RTM~M,,Lv were incubated 
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Fig.2. Effect of serine proteinase on the polymerase activity of RT ~~~“rv. Residual activity of RTM~M”LV was 
determined after pretreatment with various concentrations of the following proteases: (1,7,12) without protease; (2) 
26 U (208 ng) TSP-1; (3) 13 U (104 ng) TSP-1; (4) 6 U (52 ng) TSP-1; (5) 3 U (26 ng) TSP-1; (6) 26 U (208 ng) TSP-1 
and PMSF (3 mM); (8) 26 U p-kallikrein; (9) 130 U p-kallikrein; (10) 26 U (32.5 ng) t-kallikrein; (11) 13 U (16 ng) t- 
kallikrein; (13) 26 U (49 ng) trypsin; (14) 13 U (25 ng) trypsin; (15) 26 U (49 ng) trypsin and PMSF (3 mM); (16) PMSF 
(3 mM) alone. The reverse transcriptase assay was performed as described in section 2. (M) Size-markers (pBR322 HinfI 
fragments in bases) are shown to the left. 
with purified preparations of TSP-1, kallikrein (t) 
or with pancreatic trypsin, previously adjusted to 
express similar amidolytic activity on PFR-NA. 
Subsequently, the samples were fractionated on 
SDS-PAGE under reducing conditions and anal- 
ysed by protein staining. The serine proteinases on 
their own were either undetectable or showed up as 
very faint bands under these conditions. The 
preparation of the cloned RTM~M~LV (>99% puri- 
ty) showed a protein band of 80 kDa (fig.3, lane 
lo), in agreement with the molecular mass of the 
viral enzyme [3 11. Treatment of RTM~M~LV with 
TSP-1 resulted in the disappearance of the RT- 
specific band and the appearance of two major and 
one minor species with a molecular mass around 
33, 18 and 31 kDa, respectively (fig.3, lane 1). 
Pretreatment of TSP-1 with either PMSF or PFR- 
CK abolished its proteolytic activity on RTM~M”LV 
(fig.3, lanes 2,3). The inhibitors alone had no ef- 
fect on the polymerase’s integrity (fig.3, lanes 4,5) 
and also did not influence the activity of RTMOM~LV 
(fig.2, lane 16). Furthermore, RT~WM”LV was also 
partially cleaved by t-kallikrein (fig.3, lane 6). 
Moreover, only one minor band with a molecular 
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Fig.3. SDS-PAGE analysis (reducing conditions) of 
RTM,,M”L~. Proteolytic degradation of RTM~M”LV was 
tested after pretreatment with the following proteases: 
(1) 26 U (208 ng) TSP-1; (2) 26 U (208 ng) TSP-1 and 
PFR-CK (1 mM); (3) 26 U (208 ng) TSP-1 and PMSF 
(3 mM); (4) PFR-CK (1 mM) alone; (5) PMSF (3 mM) 
alone; (6) 26 U (32.5 ng) t-kallikrein; (7) 26 U (32.5 ng) 
t-kallikrein and PMSF (3 mM); (8) 26 U (49 ng) trypsin; 
(9) 26 U (49 ng) trypsin and PMSF (3 mM); (10) without 
protease. SDS-PAGE analysis and staining of protein 
with silver nitrate was done as described insection 2. (M) 
Relative molecular mass markers (in thousands) are 
shown on the left. 
mass of 30 kDa was seen after pretreatment of 
RT~vlo~“rv with pancreatic trypsin (fig.3, lane 8) in- 
dicating a more pronounced degradation of 
RTM~M~LV . Proteolytic activity of both serine pro- 
teinases, t-kallikrein and pancreatic trypsin, on 
RTM,,M,,~~ was reduced to a great extent following 
treatment with PMSF (fig.3, lanes 7,9). 
4. DISCUSSION 
This study demonstrates that RTM~M”LV is a 
suitable substrate for the T cell-associated serine 
proteinase TSP-1 which destroys the enzyme ac- 
tivity of RTM~M~LV via limited proteolysis resulting 
in only few distinct degradation products. Similar 
results were also obtained using a reverse transcrip- 
tase preparation derived from avian myeloblastosis 
virus (not shown). Since the deduced protein se- 
quence of RTM~M~J_v does not contain the tripep- 
tide sequence PFR per se [32] it is likely that 
several tripeptide sequences with the primary AA 
arginine and AA substituents in positions PZ and 
P3 quite similar to that of PFR like Phe-Pro-Arg 
(FPR), Pro-Tyr-Arg (PYR) and Pro-Trp-Arg 
(PWR) serve as target structures for TSP-1. One 
could also imagine that the AA sequence in the 
model peptide mimics a similar AA composition 
formed by three-dimensional folding in the native 
substrate [24]. 
Is there any significance of this finding with 
respect to T cell-mediated antiviral defense 
mechanisms? Experimental work in mouse and 
man suggests the importance of CTLs in the con- 
trol of virus replication. The generation of CTLs 
has been demonstrated for both DNA and RNA 
viruses including retroviruses such as murine sar- 
coma virus [33], Friend [34,35], Rauscher [36], 
AKR/Gross LV [36,37] and MoMuLV [38]. In 
several in vivo studies it was shown that cloned 
virus-specific CTLs protect mice against lethal 
virus infections [2-41. However, although these 
results were taken as evidence that the elimination 
of virus from the host was due to lysis of infected 
target cells there is no direct evidence yet for this 
T cell-effector function in vivo. More recently, 
Walker et al. [39] have demonstrated that CD8+ 
lymphocytes derived from HIV antibody positive 
individuals were able to suppress HIV replication 
in selected CD4+ cells in vitro at the initiation of 
retrovirus production as well as after several weeks 
of retrovirus replication by cultured CD4+ cells. 
The data suggested that CD8+ cells do not inhibit 
virus replication by suppression or lysis of HIV- 
infected CD4+ cells but rather by an as yet 
undefined soluble mediator distinct from IFNy. It 
has been shown recently that the CTL-target cell 
interaction is accompanied by directed granule ex- 
ocytosis [40-421. Thus, since TSP-1 is associated 
with cytoplasmic granules of CTL [ 10,12,15] and is 
specifically released by CTLs into the extracellular 
space upon contact with target cells [11,14,16], 
TSP-1 may interact with proteins from virus par- 
ticles following CTL-target cell interaction. At pre- 
sent one can only speculate on how soluble TSP-1 
could meet and react with its substrate RT. It is 
possible that the serine proteinase is bound to and 
endocytosed together with intact viruses resulting 
in accumulation of both entities in the cytoplasma 
of newly infected cells. Alternatively, TSP-1 may 
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be internalized during constitutive endocytosis 
events by infected cells. TSP-1 may also penetrate 
into host cells during the CTL-target cell interac- 
tion possibly via membrane channels formed by 
cytolysin/perforin molecules in target cell mem- 
branes [40-421. All hypothetical processes could 
facilitate an encounter of TSP-1 with retroviral RT 
in appropriate compartments of the cytosol 
resulting in blockade of the key step in the 
reproductive cycle of retroviruses - copying the 
single-stranded RNA genome into double-stranded 
DNA [26] - by cleaving RT present in the virion 
after its uncoating. 
However, it is also possible that proteins of the 
envelope of intact retroviruses are substrates for 
TSP-1. In this case, TSP-1 might interfere with the 
binding of virus particles to cell surface receptors 
by degrading anti-receptor determinants via 
limited proteolysis. The fact that the envelope pro- 
tein of MoMuLV contains multiple AA tripeptide 
sequences imilar to PFR has prompted us to in- 
itiate studies in this direction. 
The message of this study is that CTLs express 
and secrete a serine proteinase which has the ability 
to cleave and inactivate the retroviral protein RT. 
Although the mechanism(s) of interference with 
retroviral replication by CTLs is (are) far from be- 
ing resolved, the finding reported here offers a new 
approach to investigate the T cell-mediated control 
of retroviral infections. 
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